Surveillance and Epidemiology of Drug-Resistant Infections Consortium (SEDRIC): Supporting the transition from strategy to action
Keiji Fukuda, Direk Limmathurotsakul, Direk Limmathurotsakul, Nandini Shetty, Rogier van Doorn, Nicholas A. Feasey, Francesca Chiara, Ghada Zoubiane, Tim Jinks, Julian Parkhill, Jean Patel, Stuart W.J. Reid, Alison H. Holmes, Sharon J. Peacock and SEDRIC
27 June, 2018
Access via 'The National Center for Biotechnology Information'
Publication summary
This paper outlines the aims of SEDRIC and highlights areas for action. Surveillance and epidemiology are central in the control of antibiotic resistance. There is a clear need to intensify the generation, collection, collation and distribution of high-quality epidemiological data. SEDRIC (Surveillance and Epidemiology of Drug-Resistant Infections Consortium) was established to improve surveillance and aims to strengthen the availability of information needed to monitor and track the spread of resistance. SEDRIC has brought together experts to promote the use of evidence to inform the design of effective public health interventions and changes in policy globally.
Who this is for
- Policymakers and civil servants working in AMR
- AMR surveillance and epidemiology specialists
- Pharmaceutical industry
Key findings
- We need to identify barriers to effective surveillance
- There is a great need for technological innovation to develop standardised and harmonised data collection tools
- We must maximise data use from private and public organisations to inform policy-making on surveillance and epidemiology of antimicrobial resistance (AMR)
Share this publication
Apply to become a member
Are you working in AMR surveillance and epidemiology? Join SEDRIC today to start communicating and collaborating with our community of experts.
Apply to become a member